Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem acquires license to stem cell delivery system
The exclusive, worldwide license to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, University of California, San
The exclusive, worldwide license to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, University of California, San
On October 26, 2007, Aviation Upgrade Technologies (AVUG), which ceased all previous business operations on August 16, 2007, entered into an agreement and plan of merger with OncoVista
The Nephros OLpur MD hemodiafilter series received CE Marking in 2003 and is currently in use in over 50 European clinics. The OLpur H2H hemodiafiltration module is designed
Uroplasty has granted the underwriters a 30-day option to purchase up to an additional 219,960 shares of common stock at the offering price to cover over-allotments. The proceeds
This license agreement is a result of Medical Aesthetics Technology Corporation’s (MATC’s) exercise of a previously signed option agreement. Under the agreement, MATC is responsible for continued development
In the study, 25 patients with advanced malignant gliomas were treated with a loading dose of 600mg (150mg x 4) followed by 100mg daily dose of perifosine. Patients
As a part of these labor contracts, the union will not endorse any other dental network. In the Charlotte area, Union Dental Holdings (UDHI) has a national contract
The trial is designed to test the ability of elocalcitol to improve sperm quality in infertile male patients. Results are expected for the end of 2008. The trial
Activities will be performed in Cook Pharmica’s development laboratory within its Bloomington facility. Terms of the agreement have not been released. Jerry Arthur, president of Cook Pharmica, said:
The drug is a patented oligonucleotide that specifically blocks NF-kB, a transcription factor that activates pro-inflammatory genes, and is currently in Phase II testing for the treatment of